newsfilter
← Latest News
GlobeNewswire·

Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024

Five Investigational New Drug (IND) applications cleared across a range of therapeutic areas and FDA divisions for lead asset, IMVT-1402Proof of concept data from batoclimab trial in Graves' disease (GD) demonstrate